Stockscreener 앱 받기
3.86
3.50%
-0.14
시간 외 거래:
3.85
-0.010
-0.26%
Briacell Therapeutics Corp 주식(BCTX)의 최신 뉴스
(BCT) Investment Performance Report (BCT:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - PR Newswire
BriaCell (BCTX) Highlights Promising Biomarkers in Metastatic Br - GuruFocus
BriaCell Therapeutics Corp. - Baystreet.ca
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
How To Trade (BCT) (BCT:CA) - news.stocktradersdaily.com
BriaCell’s Phase 3 Data Shows Promise for Metastatic Breast Cancer Treatment - TipRanks
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Posit - GuruFocus
Buy This Dividend-Paying Tech Stock to Play the Low-Cost China AI Story - The Globe and Mail
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: - GlobeNewswire
Game-Changing Cancer Biomarkers: BriaCell Phase 3 Data Shows How to Predict Treatment Success - Stock Titan
Occidental’s Hidden Gem: How OxyChem Could Boost Profits - The Globe and Mail
BriaCell (BCTX) Reveals Promising Phase 2 and Preclinical Data a - GuruFocus
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Therapeutics closes $13.8M public offering - MSN
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering - The Manila Times
Briacell Therapeutics Announces Closing Of $13.8 Million Public Offering - marketscreener.com
BriaCell Secures $13.8M Funding Boost: New Capital to Accelerate Cancer Immunotherapy Development - Stock Titan
Vitalhub Corp. - Baystreet.ca
BriaCell Presents Benchmark Beating Survival and Clinical Benefi - GuruFocus
BriaCell’s Breakthrough in Cancer Immunotherapy at AACR 2025 - TipRanks
BriaCell Presents Benchmark Beating Survival and Clinical - GlobeNewswire
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development - The Manila Times
BriaCell's Breast Cancer Immunotherapy Shows Breakthrough 17.3-Month Survival in Latest Trial Data - Stock Titan
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - MSN
Littelfuse Earnings: What To Look For From LFUS - The Globe and Mail
(BCT) Trading Performance and Risk Management (BCT:CA) - news.stocktradersdaily.com
BriaCell (BCTX) Prices Public Offering of Units to Raise $13.8 M - GuruFocus
Increased Share Offering for XYZ Corp (XYZ) Priced Below Market - GuruFocus
BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offerin - GuruFocus
BriaCell Therapeutics to Raise $13.8 Million in Public Offering; Shares Fall - marketscreener.com
BriaCell's Stock Dips Following Public Offering Announcement - Finimize
BriaCell Therapeutics Down 17% In US Premarket As Prices US$13.8 Million Public Offering - marketscreener.com
BriaCell Therapeutics announces pricing of $13.8 million public offering - MSN
(BCT) Trading Report (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail’s Busy Cheering Clinical Milestone - Investing.com India
BriaCell Therapeutics Announces $13.8 Million Public Offering - TipRanks
BriaCell Raises $13.8M: Strong Institutional Demand Drives Full Exercise of Underwriter Option - Stock Titan
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering - The Manila Times
Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million - marketscreener.com
BriaCell reports complete lung metastasis resolution in breast cancer study By Investing.com - Investing.com South Africa
BriaCell's Bria-OTS shows sustained success against breast cancer | 2025-04-24 | Investing News - Stockhouse
BriaCell confirms 100% resolution of lung metastasis with Bria-OTS - TipRanks
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher - Benzinga
BriaCell (BCTX) Showcases Key Breast Cancer Trial Data at ASCO 2 - GuruFocus
BriaCell Jumps 41% in U.S. Pre-market Trading, Reports Complete Lung Metastasis Resolution in Patient - marketscreener.com
BriaCell (BCTX) Reports Positive Outcomes in Bria-OTS Cancer Study | BCTX Stock News - GuruFocus
BriaCell’s Bria-OTS Shows Promising Results in Metastatic Breast Cancer Study - TipRanks
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-O - GuruFocus
BriaCell Therapeutics stock soars on lung metastasis treatment success By Investing.com - Investing.com Nigeria
0.39%
3.66%
자본화:
|
볼륨(24시간):